CO2023004198A2 - Polipéptidos variantes de luka y lukb de staphylococcus aureus y composiciones de vacuna - Google Patents
Polipéptidos variantes de luka y lukb de staphylococcus aureus y composiciones de vacunaInfo
- Publication number
- CO2023004198A2 CO2023004198A2 CONC2023/0004198A CO2023004198A CO2023004198A2 CO 2023004198 A2 CO2023004198 A2 CO 2023004198A2 CO 2023004198 A CO2023004198 A CO 2023004198A CO 2023004198 A2 CO2023004198 A2 CO 2023004198A2
- Authority
- CO
- Colombia
- Prior art keywords
- lukb
- staphylococcus aureus
- variant polypeptides
- luka
- vaccine compositions
- Prior art date
Links
- 241000191967 Staphylococcus aureus Species 0.000 title abstract 3
- 229920001184 polypeptide Polymers 0.000 title abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 108010014603 Leukocidins Proteins 0.000 abstract 2
- 230000028993 immune response Effects 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente divulgación se refiere a polipéptidos variantes de leucocidina A (LukA) y leucocidina B (LukB) de Staphylococcus aureus y polinucleótidos que codifican los polipéptidos variantes de LukA, LukB y LukAB. La presente divulgación se refiere, además, a composiciones de vacuna que comprenden estas variantes de LukA y LukB, y métodos para generar una respuesta inmune contra Staphylococcus aureus en un sujeto.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063084273P | 2020-09-28 | 2020-09-28 | |
| PCT/US2021/052418 WO2022067255A2 (en) | 2020-09-28 | 2021-09-28 | Variant staphylococcus aureus luka and lukb polypeptides and vaccine compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2023004198A2 true CO2023004198A2 (es) | 2023-07-31 |
Family
ID=80846955
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2023/0004198A CO2023004198A2 (es) | 2020-09-28 | 2023-03-30 | Polipéptidos variantes de luka y lukb de staphylococcus aureus y composiciones de vacuna |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20240050546A1 (es) |
| EP (1) | EP4216982A2 (es) |
| JP (1) | JP2023544300A (es) |
| KR (1) | KR20230091911A (es) |
| CN (1) | CN116670158A (es) |
| AR (1) | AR123635A1 (es) |
| AU (1) | AU2021350860A1 (es) |
| CA (1) | CA3195895A1 (es) |
| CL (1) | CL2023000884A1 (es) |
| CO (1) | CO2023004198A2 (es) |
| IL (1) | IL301406A (es) |
| MX (1) | MX2023003581A (es) |
| WO (1) | WO2022067255A2 (es) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0102327D0 (sv) * | 2001-06-28 | 2001-06-28 | Active Biotech Ab | A novel engineered superantigen for human therapy |
| RU2677140C1 (ru) * | 2010-05-05 | 2019-01-15 | Нью-Йорк Юниверсити | Лейкоцидины staphylococcus aureus, терапевтические композиции и их применение |
| CN110913883A (zh) * | 2017-06-13 | 2020-03-24 | 综合生物治疗疫苗公司 | 包含金黄色葡萄球菌杀白细胞素luka和lukb来源的多肽的免疫原性组合物 |
-
2021
- 2021-09-28 MX MX2023003581A patent/MX2023003581A/es unknown
- 2021-09-28 AU AU2021350860A patent/AU2021350860A1/en active Pending
- 2021-09-28 JP JP2023519355A patent/JP2023544300A/ja active Pending
- 2021-09-28 CN CN202180065630.5A patent/CN116670158A/zh active Pending
- 2021-09-28 IL IL301406A patent/IL301406A/en unknown
- 2021-09-28 EP EP21873641.1A patent/EP4216982A2/en active Pending
- 2021-09-28 CA CA3195895A patent/CA3195895A1/en active Pending
- 2021-09-28 WO PCT/US2021/052418 patent/WO2022067255A2/en active Application Filing
- 2021-09-28 AR ARP210102696A patent/AR123635A1/es unknown
- 2021-09-28 KR KR1020237014304A patent/KR20230091911A/ko unknown
- 2021-09-28 US US18/028,477 patent/US20240050546A1/en active Pending
-
2023
- 2023-03-27 CL CL2023000884A patent/CL2023000884A1/es unknown
- 2023-03-30 CO CONC2023/0004198A patent/CO2023004198A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4216982A2 (en) | 2023-08-02 |
| KR20230091911A (ko) | 2023-06-23 |
| AU2021350860A1 (en) | 2023-05-04 |
| WO2022067255A2 (en) | 2022-03-31 |
| WO2022067255A3 (en) | 2022-04-28 |
| JP2023544300A (ja) | 2023-10-23 |
| CL2023000884A1 (es) | 2023-09-29 |
| CN116670158A (zh) | 2023-08-29 |
| IL301406A (en) | 2023-05-01 |
| AR123635A1 (es) | 2022-12-28 |
| US20240050546A1 (en) | 2024-02-15 |
| MX2023003581A (es) | 2023-06-21 |
| CA3195895A1 (en) | 2022-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR118725A2 (es) | Vectores para expresión de antígenos asociados a próstata | |
| CO2019014677A2 (es) | Vectores de poxvirus que codifican antígenos del virus de inmunodeficiencia humana (vih), y métodos de uso de los mismos | |
| MX2020004543A (es) | Vacunas contra el zika, composiciones inmunogenicas y metodos que las utilizan. | |
| CO2021003081A2 (es) | Métodos y composiciones para la modificación de plantas | |
| CL2017002694A1 (es) | Métodos para mejora hidráulica de cultivos | |
| CO2021017697A2 (es) | Mejoramientos en o relacionados con compuestos orgánicos | |
| AR094791A1 (es) | Composiciones y métodos para mejorar las respuestas inmunes ante una infección por eimeria o para limitar una infección por eimeria | |
| MX360084B (es) | Composicion de champu que comprende matriz de gel e histidina. | |
| AR115069A1 (es) | Virus vacuna quimérico sintético | |
| CL2018003026A1 (es) | Loci genéticos asociados con una mayor fertilidad en el maíz (divisional de la solicitud n° 2071-2016). | |
| CO2017011984A2 (es) | Procedimiento de protección de plantas y estructura de red | |
| CL2019002514A1 (es) | Composiciones cosméticas para el cuidado de la piel. | |
| CO2019003424A2 (es) | Extracto de planta impregnado de alulosa y método de preparación para el mismo | |
| ECSP18081582A (es) | Constructos de alfavirus vivo atenuado y métodos y usos de los mismos | |
| CL2018000513A1 (es) | Vacunas de pestivirus para temblores congénitos | |
| CL2019002516A1 (es) | Composiciones cosméticas para el cuidado de la piel. | |
| MX2017004535A (es) | Mejoramientos en o con relacion a compuestos organicos. | |
| CO2023004198A2 (es) | Polipéptidos variantes de luka y lukb de staphylococcus aureus y composiciones de vacuna | |
| BR112018073254A2 (pt) | adjuvante agrícola | |
| MX2020004677A (es) | Composiciones pesticidas y metodos relacionados. | |
| CO2021012174A2 (es) | Microorganismo perteneciente al género staphylococcus que produce alulosa y procedimiento para la preparación de alulosa mediante el uso del mismo | |
| AR101736A1 (es) | Composiciones que contienen zinc, con aceites esenciales | |
| DOP2020000104A (es) | Métodos de uso y composiciones que contienen dulaglutida | |
| AR113729A1 (es) | Plantas que tienen mayor tolerancia a herbicidas | |
| CO2023002828A2 (es) | Composición insecticida sinérgica |